Preliminary anti-Coxsackie activity of novel 1-[4-(5,6-dimethyl(H)-1H(2H)-benzotriazol-1(2)-yl)phenyl]-3-alkyl(aryl)ureas.

Clicks: 348
ID: 81877
2019
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Coxsackievirus infections are associated with cases of aseptic meningitis, encephalitis, myocarditis, and some chronic disease.A series of benzo[d][1,2,3]triazol-1(2)-yl derivatives (here named benzotriazol-1(2)-yl) (4a-i, 5a-h, 6a-e, g, i, j and 7a-f, h-j) were designed, synthesized and in vitro evaluated for cytotoxicity and antiviral activity against two important human enteroviruses (HEVs) members of the Picornaviridae family [Coxsackievirus B 5 (CVB-5) and Poliovirus 1 (Sb-1)].Compounds 4c (CC50 >100 μM; EC50 = 9 μM), 5g (CC50 >100 μM; EC50 = 8 μM), and 6a (CC50 >100 μM; EC50 = 10 μM) resulted interestingly active against CVB-5. With the aim of evaluating the selectivity of action of this class of compounds, a wide spectrum of RNA (positive- and negative-sense), double-stranded (dsRNA) or DNA viruses were also assayed. For none of them, significant antiviral activity was determined.Taken together these results point towards a selective activity against CVB-5, an important human pathogen that causes both acute and chronic diseases in infants, young children, and immunocompromised patients.
Reference Key
piras2019preliminarymedicinal Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Piras, Sandra;Corona, Paola;Ibba, Roberta;Riu, Federico;Murineddu, Gabriele;Sanna, Giuseppina;Madeddu, Silvia;Delogu, Ilenia;Loddo, Roberta;Carta, Antonio;
Journal medicinal chemistry (shariqah (united arab emirates))
Year 2019
DOI
10.2174/1573406416666191226142744
URL
Keywords
Cytotoxicity rna virus antiviral activity enterovirus benzotriazole derivatives coxsackievirus picornaviridae

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.